Zilch Accelerates Growth and Halves Costs with Taktile’s Next-Generation Decision Platform
Zilch, the world’s first ad-subsidized payments network (ASPN), transforms its underwriting infrastructure with Taktile’s risk decision platform, boosting efficiency and lowering provider and usage costs.
Zilch, the fintech payments innovator of the world’s first ad-subsidized payments network (ASPN), has revolutionized its underwriting infrastructure, achieving savings by reducing provider and usage costs by over half by transitioning to Taktile, a cutting-edge decisioning platform. This strategic shift not only enhances Zilch’s operational efficiency but also supports the company’s sustained growth in the highly competitive financial technology sector.
Pioneering Change in Consumer Payments
As a frontrunner in consumer payments, Zilch’s vision is to eliminate the high cost of consumer credit, for good. It empowers consumers to make purchases anywhere, anytime, without the burden of falling into revolving debt traps that cost consumers $150bn in interest and fees in just the US and UK alone. Having saved its 4m+ customers over $600m since launch in 2020 and as the first regulated credit product of its kind in the BNPL industry, Zilch’s ambitious target is to reduce that $150bn to zero, to Zilch. To continue delivering on this vision and recognizing the rapid advances in decisioning software, Zilch saw the need to modernize its credit underwriting processes to provide greater resilience, flexibility, and scalability.
The Solution: Taktile’s Transformative Platform
Under the leadership of Zilch’s Chief Risk Officer, Des Mcnamara, Chanuka Perera, Head of Credit Risk at Zilch, led the search for a platform that could align with Zilch’s ambitious growth plans. After an extensive evaluation of several automated decisioning tools, Taktile emerged as the clear choice, offering the flexibility and innovation that Zilch needed.
“Taktile’s platform has empowered our teams to take control of our automated underwriting processes, allowing us to build, test, and optimize decisions with unprecedented speed and independence,” said Chanuka Perera. “This shift has not only streamlined our operations but has also resulted in significant cost savings, freeing up resources for further innovation.”
Seamless Integration and Empowerment
The transition to Taktile was swift and seamless, with Zilch completing the migration and going live with the new system in just four weeks. Taktile’s intuitive user interface, featuring pre-built “Nodes,” enables Zilch’s subject matter experts to create and refine underwriting decisions without the need for external support or technical expertise.
Taktile’s Data Marketplace, which includes a vast library of pre-built data integrations, further simplified Zilch’s operations by providing easy access to essential data providers. This self-serve capability has empowered Zilch’s credit and risk teams to rapidly develop, test, and optimize decision flows, significantly reducing reliance on external consultants.
A Strategic Move for Long-Term Success
The impact of adopting Taktile extends beyond immediate cost savings. With a flexible, scalable platform, Zilch is now more robustly equipped to navigate the complexities of its rapidly scaling global operations and respond to evolving market demands.
“We see our partnership with Taktile as a notable driver of our success to date and one that’ll grow stronger. By reducing costs and increasing agility, we are now more prepared than ever to meet the needs of our customers and expand our reach,” added Perera.
About Zilch
Zilch’s vision is to eliminate the high cost of consumer credit. For good.
Zilch is a multi-award-winning pioneer of the world’s first direct-to-consumer, ad-subsidised payments network (ASPN). Leveraging its unique, vertically integrated, first-party-data business model, Zilch sets itself apart from the incumbent fintech industry with a profitable global revenue source, bringing unrivalled value to customers and marketers alike. Today, Zilch is revolutionising the $50 trillion advertising and payments industries by merging the very best of debit, credit, and savings.
Co-founded by Philip Belamant, Sean O’Connor, and Serge Belamant, Zilch provides millions of customers the freedom to go anywhere in the world (online or offline) and, when they pay, earn up to 5% cashback & rewards on debit payments (‘Pay Now’) or spread interest-free credit repayments over six weeks or three months. In the process, Zilch helps customers build their credit profiles with the major credit agencies. Within 44 months since its launch in 2020, Zilch amassed more than 4 million registered customers.
In September 2024, four years after its public launch in 2020, Zilch announced that in July 2024, it had achieved first-month profitability in record time while surpassing $130 million in revenue run rate, keeping pace with European fintech giants like Revolut, Starling Bank, and Monzo.
In 2023, Zilch launched its proprietary ASPN service, which allows merchants worldwide instant connection with Zilch’s first-party-data, closed-loop network of millions of high-intent customers, while offering customers personalised savings, deals, and discounts codified to their habitual daily spend.
In January 2023, Zilch struck a ground-breaking reporting agreement with the UK’s prime credit reference agencies, transforming the UK lending ecosystem by enabling all adults to build their credit records using interest-free credit rather than high-cost revolving credit products.
Since April 2020, Zilch has been regulated by the Financial Conduct Authority (FCA), obtaining a consumer credit licence through the Regulatory Sandbox Programme.
Driven by innovation and a commitment to excellence, Zilch is setting new benchmarks in the industry to create a more inclusive and efficient ecosystem, empowering millions of users to budget and manage their financial lives more effectively and transparently.
For more information, visit: www.zilch.com.
About Taktile
Taktile is a next-generation decision platform that empowers subject matter experts to build, monitor, and optimize automated risk decisions across the entire customer lifecycle—from credit underwriting and onboarding & KYC/KYB to transaction monitoring and collections. With its low-code UI and best-in-class marketplace of third-party data integrations, Taktile enables credit, fraud, and risk teams to reduce reliance on engineering, adapt quickly to market changes, and ultimately drive growth while lowering operational costs.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241106270583/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Microba Announces Landmark GI Study Results From Over 4,600 Patients15.5.2025 04:12:00 CEST | Press release
Results at a glance:71.4% of MetaXplore™ reports from 4,616 patients identified actionable results41.9% tested positive for abnormal microbiome markers linked to gastrointestinal health9.9% tested positive for gastrointestinal markers, including inflammation, pancreatic insufficiency, or blood in stool19.6% of reports tested positive for multiple markers (microbiome and gastrointestinal)65% of patients reported health improvements following clinician-directed recommendations informed by MetaXplore Microba Life Sciences Limited (ASX: MAP) (“Microba” or the “Company”), a precision microbiome company, today announces preliminary results from the analysis of over 4,600 MetaXplore™ GI Plus test results, a comprehensive test for the assessment and management of lower gastrointestinal disorders, spanning symptoms including chronic pain, bloating, constipation, or diarrhea. This study demonstrates that MetaXplore can support clinicians to identify and address underlying gut issues that often g
Bloomstreet Enters into Strategic Partnership Agreement with Google Israel for Market Expansion in Japan15.5.2025 04:00:00 CEST | Press release
Optimizing Global Websites for the Japanese Visitors: Detailed UX/UI Adaptation, Comprehensive Japanese Localization, Extensive Localization and Cultural Relevance to Fit the Local Audience. Bloomstreet Inc. (Headquarters: Chuo-ku, Tokyo; President & CEO: Junichi Takayama; hereinafter “Bloomstreet”), a company that supports overseas enterprises entering the Japanese market, is pleased to announce a strategic partnership agreement with Google Israel Ltd. (Headquarters: Tel Aviv District; Country Manager: Barak Regev; hereinafter “Google Israel”). This partnership aims to support Israeli companies that operate globally with Google Ads and are seeking to expand into the Japanese market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250514387485/en/ How do Bloomstreet and Google Israel collaborate? The partnership between Bloomstreet and Google Israel is designed to support Israeli companies seeking to expand into the Japanese
Rubedo Life Sciences’ Drug Discovery Platform, ALEMBIC™, Helps Identify Senescent or “Zombie” Neurons in New Study Linking Neuropathic Pain and Aging Published in Peer-Reviewed Scientific Journal Nature Neuroscience15.5.2025 03:11:00 CEST | Press release
Study is the first demonstration of senescent neurons driving neuropathic pain1 Rubedo’s proprietary, AI-driven drug discovery platform ALEMBIC™ identified senescent neurons as novel therapeutic targets2 Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on discovering and rapidly developing selective cellular rejuvenation medicines targeting aging cells, today announced that using open source codes integrated in the company’s broader propriety drug discovery platform, ALEMBIC™, helped to identify senescent neurons in a new study that found senescent neurons drive chronic pain with injury and age.1 Senescent cells, often called “zombie” cells, arise as the results of cellular stress and damage. These senescent cells do not die but undergo cellular changes, including secreting pro-inflammatory factors, thereby potentially contributing to inflammatory responses within the body.1 The study, led by Stanford University scientists, Vivianne Tawfik, MD, PhD, and
The New England Journal of Medicine Publishes Data from Phase 2b Trial of Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) in People with Narcolepsy Type 114.5.2025 23:03:00 CEST | Press release
–Data Demonstrated Statistically Significant Improvements in Primary and Secondary Endpoints with Most Subjects Achieving Near Normal Ranges of Wakefulness and Clinically Meaningful Improvements Across the Broad Range of Symptoms Investigated–Oveporexton Found to be Generally Safe and Well Tolerated–Phase 3 Readout of Oveporexton Anticipated in 2025 Takeda (TSE: 4502/NYSE:TAK) today announced that the New England Journal of Medicine published data from the Phase 2b trial of oveporexton (TAK-861) in people with narcolepsy type 1 (NT1). Oveporexton is an investigational oral orexin receptor 2 (OX2R)-selective agonist designed to restore orexin signaling to address the underlying orexin deficiency that causes NT1. Results demonstrated significant improvement in objective and subjective measures of excessive daytime sleepiness (EDS), reductions in cataplexy events and clinically meaningful improvements in disease severity and quality of life across all doses tested compared to placebo thro
BeiGene Showcases Strength of Hematology Portfolio at EHA 2025 with New Data Highlighting BRUKINSA’s Leadership and Next-Generation Innovation14.5.2025 22:05:00 CEST | Press release
Data across 31 abstracts illustrate BeiGene’s deep commitment to transforming treatment for B-cell malignanciesFour oral presentations highlight updated data from investigational BTK protein degrader BGB-16673 and BCL2 inhibitor sonrotoclax across a range of B-cell malignancies BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines Ltd., today announced it will share data across a range of hematologic malignancies at the European Hematology Association (EHA) Congress in Milan, Italy, June 12–15. BeiGene has 31 abstracts accepted at EHA 2025, with four selected for oral presentations, featuring data from its best-in-class Bruton’s tyrosine kinase (BTK) inhibitor BRUKINSA® (zanubrutinib) and its investigational pipeline assets – a next-generation BCL2 inhibitor, sonrotoclax, and BTK protein degrader, BGB-16673. These data reflect BeiGene’s vision to redefine standards of care in hematology through next-generation scie
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom